Telix Pharmaceuticals Ltd
ASX:TLX

Watchlist Manager
Telix Pharmaceuticals Ltd Logo
Telix Pharmaceuticals Ltd
ASX:TLX
Watchlist
Price: 24.62 AUD -1.01% Market Closed
Market Cap: 8.2B AUD
Have any thoughts about
Telix Pharmaceuticals Ltd?
Write Note

Telix Pharmaceuticals Ltd
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Telix Pharmaceuticals Ltd
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Telix Pharmaceuticals Ltd
ASX:TLX
Cash from Operating Activities
AU$23.9m
CAGR 3-Years
130%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Immutep Ltd
ASX:IMM
Cash from Operating Activities
-AU$35.4m
CAGR 3-Years
-26%
CAGR 5-Years
-18%
CAGR 10-Years
-10%
Mesoblast Ltd
ASX:MSB
Cash from Operating Activities
-$48.5m
CAGR 3-Years
22%
CAGR 5-Years
3%
CAGR 10-Years
N/A
CSL Ltd
ASX:CSL
Cash from Operating Activities
$2.8B
CAGR 3-Years
-9%
CAGR 5-Years
11%
CAGR 10-Years
7%
Clinuvel Pharmaceuticals Ltd
ASX:CUV
Cash from Operating Activities
AU$37.1m
CAGR 3-Years
24%
CAGR 5-Years
15%
CAGR 10-Years
N/A
PYC Therapeutics Ltd
ASX:PYC
Cash from Operating Activities
-AU$38.6m
CAGR 3-Years
-48%
CAGR 5-Years
-50%
CAGR 10-Years
-28%
No Stocks Found

Telix Pharmaceuticals Ltd
Glance View

Market Cap
8.2B AUD
Industry
Biotechnology
Economic Moat
Wide

Telix Pharmaceuticals Ltd. is an innovative biopharmaceutical company that has carved a niche for itself in the realm of targeted radiation therapy and imaging, primarily focusing on cancer treatment. Established with the vision of transforming the landscape of oncology, Telix develops molecularly-targeted radiation (MTR) products aimed at diagnosing and treating a range of significant unmet medical needs. The company's lead product, Illuccix, gained significant attention after securing regulatory approvals for use in imaging prostate cancer. Through strategic alliances with academic and research institutions, as well as commercial entities, Telix harnesses the power of radioisotopes to create compounds that bind to specific cancer cells, allowing for both precise imaging and treatment of malignancies. The business model of Telix hinges on a blend of research and development, regulatory acumen, and strategic commercialization. By advancing a pipeline of diagnostic and therapeutic radiopharmaceuticals, Telix aims to address the full cycle of cancer care—from early detection to personalized treatment. Revenue is primarily generated through the sale of its approved products, alongside potential milestone payments and royalties from partnerships. The commercial success of Illuccix and other pipeline candidates underscores the company's ability to effectively translate scientific research into marketable therapies, positioning Telix as a formidable player in the competitive arena of cancer diagnosis and treatment. By continuing to expand its portfolio and push the boundaries of nuclear medicine, Telix seeks to deliver life-changing therapies while driving sustainable growth.

TLX Intrinsic Value
16.51 AUD
Overvaluation 33%
Intrinsic Value
Price

See Also

What is Telix Pharmaceuticals Ltd's Cash from Operating Activities?
Cash from Operating Activities
23.9m AUD

Based on the financial report for Dec 31, 2023, Telix Pharmaceuticals Ltd's Cash from Operating Activities amounts to 23.9m AUD.

What is Telix Pharmaceuticals Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 3Y
130%

The average annual Cash from Operating Activities growth rates for Telix Pharmaceuticals Ltd have been 130% over the past three years .

Back to Top